Retrospective analysis of a cohort of 41 *de novo* B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)

Caroline Algrin,[1*] Louis Pérol,[2*] Elise Chapiro,[3,4*] Lucile Baseggio,[5] Karim Maloum,[6] Catherine Settegrana,[7] Jean-François Lesesve,[8] Justine Siavellis,[9] Alain Delmer,[10] Anne-Sophie Michallet,[11] Emmanuelle Ferrant,[12] Pierre Feugier,[13] Cécile Tomowiak,[14] Annie Brion,[15] David Ghez,[16] Luc-Matthieu Fornecker,[17] Sarah Ivanoff,[9] Stéphanie Struski,[18] Laurent Sutton,[19] Isabelle Radford-Weiss,[20] Virginie Eclache,[21] Christine Lefebvre,[22] Véronique Leblond,[2] Florence Nguyen-Khac,[3,4#] and Damien Roos-Weil[2,4#] for the FILO (French Innovative Leukemia Organization) group, see Appendix below.

[1]Groupe Hospitalier Mutualiste de Grenoble, Service d'Onco-Hématologie, Grenoble; [2]Sorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris; [3]Sorbonne Université, Unité de Cytogénétique Hématologique, Hôpital Pitié-Salpêtrière, AP-HP, Paris; [4]Centre de Recherche des Cordeliers, INSERM, Drug Resistance in Hematological Malignancies (DRIHM) Team, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris; [5]Hôpital Lyon Sud, Laboratoire d'Hématologie, Hospices Civils de Lyon, Pierre-Bénite; [6]Sorbonne Université, Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, AP-HP, Paris; [7]Hôpital Ambroise Paré, Laboratoire d'Hématologie, AP-HP, Boulogne-Billancourt; [8]CHRU Nancy, Service d'Hématologie Biologique, INSERM 1256 NGERE, Nancy; [9]Hôpital Avicenne, Service d'Hématologie Clinique, AP-HP, Bobigny; [10]CHU Reims, Service d'Hématologie Clinique, Reims; [11]Centre Léon Bérard, Service d'Hématologie Clinique, Lyon; [12]Hôpital Lyon Sud, Service d'Hématologie Clinique, Hospices Civils de Lyon, Pierre-Bénite; [13]CHU Nancy, Service d'Hématologie Clinique, Vandœuvre-lès-Nancy; [14]CHU Poitiers, Service d'Hématologie Clinique, Poitiers; [15]CHU J Minjoz, Service d'Hématologie Clinique, Besançon; [16]Institut Gustave Roussy, Service d'Hématologie Clinique, Villejuif; [17]Service d'Hématologie, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg; [18]IUCT Oncopole - Toulouse, Laboratoire d'hématologie/Plateau Technique Hématologie-Oncologie, Toulouse; [19]CHU Tours, Service d'Hématologie Clinique, Tours; [20]CHU Necker-Enfants Malades, Laboratoire de Cytogénétique, APHP, Paris; [21]Hôpital Avicenne, Service d'Hématologie Biologique, AP-HP, Bobigny and [22]CHU Grenoble Alpes, Laboratoire de Cytogénétique des Hémopathies, Grenoble, France

CA, LP and EC contributed equally as co-first authors.
FNK and DRW contributed equally as co-senior authors.

Correspondence:
C. ALGRIN - caroline.algrin@avec.fr
D. ROOS-WEIL - damien.roosweil@aphp.fr

https://doi.org/10.3324/haematol.2022.282162

SUPPLEMENTARY DATA

SUPPLEMENTARY TABLES

Supplementary Table S1. Characteristics at diagnosis according to the del17p status.

Parameter	no del17p (n=24)	del17p (n=16)	p value
Age at diagnosis, years			
Median (range)	71 (51-88)	74 (46-87)	0.5
Sex, n/N (%)			
Women	8/24 (33%)	8/16 (50%)	0.3
Constitutional symptoms, n/N (%)			
Yes	4/18 (22%)	0/10 (0%)	0.3
Splenomegaly, n/N (%)			
Present	13/22 (59%)	11/16 (69%)	0.5
Lymphadenopathy, n/N (%)			
Present	6/22 (27%)	5/16 (31%)	0.9
Extranodal disease, n/N (%)			
Present	1/18 (6%)	3/13 (23%)	0.3
Lymphocytes, 10^9/L			
Median (range)	19 (5-137)	56 (9-227)	0.04
Prolymphocytes, % among lymphocytes			
Median (range)	83 (66-100)	80 (61-94)	0.4
Hemoglobin value, g/dL			
Median (range)	13 (8-17)	10 (8-14)	0.2
Platelets, 10^9/L			
Median (range)	147 (72-316)	130 (25-210)	0.12
LDH, n/N %			
Increased	7/13 (54%)	8/10 (80%)	0.4
Beta-2-microglobulin, n/N (%)			
Increased	4/8 (50%)	7/8 (88%)	0.3
Complex karyotype, n/N (%)			
Present	13/24 (54%)	15/16 (94%)	0.01
Highly complex karyotype, n/N (%)			
Present	5/24 (21%)	14/16 (88%)	< 0.001
***TP53* mutation, n/N (%)**			
Present	2/15 (13%)	7/7 (100%)	< 0.001
***MYC* gain or rearrangement, n/N (%)**			
Present	21/24 (88%)	8/16 (50%)	0.01

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure S1. Response to different first-line therapies (CT, chemotherapy, n=9; CIT, chemoimmunotherapy, n=15; BTKi, BTK inhibitor, n=5; alemtuzumab, n=3). CCR, clinical complete response; PR, partial response; SD, stable disease; PD, progressive disease. Response to therapy was evaluated using modified criteria from those of iwCLL[1]. Patients meeting iwCLL clinical and laboratory complete remission criteria were considered as in clinical complete remission (CCR) as previously described[2]. Partial response (PR), stable (SD) and progressive disease (PD) were defined using the iwCLL criteria. Overall response rate (ORR) was defined as the addition of PR and CCR rates. CT regimens included chlorambucil (n=4), CHOP/miniCHOP (n=2), fludarabine-cyclophosphamide (n=2), intensive polychemotherapy (LMBA-02 protocol) (n=1). CIT regimens included fludarabine-rituximab (FR) (n=1), fludarabine-cyclophosphamide-rituximab (FCR) (n=4), bendamustine-rituximab (BR) (n=6), chlorambucil-rituximab (n=2), rituximab-CHOP (n=2).



Supplementary Figure S2. Outcomes of B-PLL patients in different subgroups. (A) Kaplan-Meier estimates of OS according to the asymptomatic or symptomatic presentation at diagnosis (asymptomatic B-PLL, red; symptomatic B-PLL, blue). Kaplan-Meier estimates of (**B**) OS and (**C**) PFS according to the del17p and *MYC* status at diagnosis (no del17p and no *MYC* aberration, red; del17p and no *MYC* aberration, brown; no del17p and *MYC* aberration, green; del17p and *MYC* aberration, blue). Kaplan-Meier estimates of (**D**) OS and (**E**) PFS according to the first-line treatment received (CT, chemotherapy, brown; CIT, chemoimmunotherapy, blue; BTKi, green; alemtuzumab, red). WT: wildtype.



REFERENCES

1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*. 2018;131(25):2745–2760.
2. Moore J, Baran AM, Meacham PJ, et al. Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. *Am J Hematol*. 2020;95(5):E108–E110.